(+)-schisandrin B multiple interactions EXP 6480464 schizandrin B inhibits the reaction [Carbon Tetrachloride results in increased expression of MAP4K4 mRNA] CTD PMID:31150632 (-)-demecolcine increases expression ISO RGD:1313282 6480464 Demecolcine results in increased expression of MAP4K4 mRNA CTD PMID:23649840 1,1-dichloroethene increases expression ISO RGD:1313283 6480464 vinylidene chloride results in increased expression of MAP4K4 mRNA CTD PMID:26682919 1,2-dimethylhydrazine increases expression ISO RGD:1313283 6480464 1, 2-Dimethylhydrazine results in increased expression of MAP4K4 mRNA CTD PMID:22206623 17beta-estradiol multiple interactions ISO RGD:1313282 6480464 [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of MAP4K4 mRNA, [Estradiol co-treated with Progesterone] results in decreased expression of MAP4K4 mRNA CTD PMID:20660070 , PMID:20823114 2,3,7,8-tetrachlorodibenzodioxine multiple interactions ISO RGD:1313283 6480464 [Tetrachlorodibenzodioxin co-treated with AHR gene mutant form] results in decreased expression of MAP4K4 mRNA CTD PMID:19465110 2,3,7,8-tetrachlorodibenzodioxine decreases expression EXP 6480464 Tetrachlorodibenzodioxin results in decreased expression of MAP4K4 mRNA CTD PMID:33387578 2,3,7,8-tetrachlorodibenzodioxine affects expression EXP 6480464 Tetrachlorodibenzodioxin affects the expression of MAP4K4 mRNA CTD PMID:34747641 2,3,7,8-tetrachlorodibenzodioxine affects expression ISO RGD:1313283 6480464 Tetrachlorodibenzodioxin affects the expression of MAP4K4 mRNA CTD PMID:21570461 2,3,7,8-tetrachlorodibenzodioxine decreases expression ISO RGD:1313282 6480464 Tetrachlorodibenzodioxin results in decreased expression of MAP4K4 mRNA CTD PMID:20106945 , PMID:21632981 4,4'-sulfonyldiphenol increases expression ISO RGD:1313283 6480464 bis(4-hydroxyphenyl)sulfone results in increased expression of MAP4K4 mRNA CTD PMID:33297965 4-hydroxyphenyl retinamide increases expression ISO RGD:1313283 6480464 Fenretinide results in increased expression of MAP4K4 mRNA CTD PMID:28973697 6-propyl-2-thiouracil increases expression EXP 6480464 Propylthiouracil results in increased expression of MAP4K4 mRNA CTD PMID:24780913 acetamide increases expression EXP 6480464 acetamide results in increased expression of MAP4K4 mRNA CTD PMID:31881176 acetylsalicylic acid decreases expression ISO RGD:1313282 6480464 Aspirin results in decreased expression of MAP4K4 mRNA CTD PMID:15928584 aconitine increases expression EXP 6480464 Aconitine results in increased expression of MAP4K4 protein CTD PMID:33236894 acrolein multiple interactions ISO RGD:1313282 6480464 [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone] results in increased expression of MAP4K4 mRNA, [Air Pollutants results in increased abundance of [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone]] which results in increased expression of MAP4K4 mRNA CTD PMID:32699268 aflatoxin B1 increases expression ISO RGD:1313283 6480464 Aflatoxin B1 results in increased expression of MAP4K4 mRNA CTD PMID:19770486 aflatoxin B1 increases methylation ISO RGD:1313282 6480464 Aflatoxin B1 results in increased methylation of MAP4K4 exon CTD PMID:30157460 all-trans-retinoic acid decreases expression ISO RGD:1313282 6480464 Tretinoin results in decreased expression of MAP4K4 mRNA CTD PMID:33167477 alpha-pinene multiple interactions ISO RGD:1313282 6480464 [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone] results in increased expression of MAP4K4 mRNA, [Air Pollutants results in increased abundance of [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone]] which results in increased expression of MAP4K4 mRNA CTD PMID:32699268 amphetamine decreases expression EXP 6480464 Amphetamine results in decreased expression of MAP4K4 mRNA CTD PMID:30779732 antirheumatic drug increases expression ISO RGD:1313282 6480464 Antirheumatic Agents results in increased expression of MAP4K4 mRNA CTD PMID:24449571 arsenite(3-) multiple interactions ISO RGD:1313282 6480464 arsenite inhibits the reaction [G3BP1 protein binds to MAP4K4 mRNA] CTD PMID:32406909 benzo[a]pyrene increases expression ISO RGD:1313283 6480464 Benzo(a)pyrene results in increased expression of MAP4K4 mRNA CTD PMID:19770486 more ... benzo[a]pyrene increases expression ISO RGD:1313282 6480464 Benzo(a)pyrene results in increased expression of MAP4K4 mRNA CTD PMID:32234424 benzo[a]pyrene affects methylation ISO RGD:1313282 6480464 Benzo(a)pyrene affects the methylation of MAP4K4 promoter CTD PMID:27901495 benzo[a]pyrene multiple interactions ISO RGD:1313283 6480464 [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MAP4K4 mRNA CTD PMID:27858113 benzo[a]pyrene decreases expression ISO RGD:1313282 6480464 Benzo(a)pyrene results in decreased expression of MAP4K4 mRNA CTD PMID:20106945 more ... benzo[a]pyrene diol epoxide I decreases expression ISO RGD:1313282 6480464 7 more ... CTD PMID:19150397 benzo[b]fluoranthene increases expression ISO RGD:1313283 6480464 benzo(b)fluoranthene results in increased expression of MAP4K4 mRNA CTD PMID:26377693 benzo[b]fluoranthene multiple interactions ISO RGD:1313283 6480464 [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MAP4K4 mRNA CTD PMID:27858113 bisphenol A increases expression EXP 6480464 bisphenol A results in increased expression of MAP4K4 mRNA CTD PMID:25181051 more ... bisphenol A multiple interactions ISO RGD:1313282 6480464 [bisphenol A co-treated with Fulvestrant] affects the methylation of MAP4K4 gene CTD PMID:31601247 bisphenol A affects methylation ISO RGD:1313282 6480464 bisphenol A affects the methylation of MAP4K4 gene CTD PMID:31601247 bisphenol A decreases expression ISO RGD:1313282 6480464 bisphenol A results in decreased expression of MAP4K4 protein CTD PMID:33376534 bisphenol A affects expression ISO RGD:1313282 6480464 bisphenol A affects the expression of MAP4K4 mRNA CTD PMID:30903817 bisphenol A increases methylation EXP 6480464 bisphenol A results in increased methylation of MAP4K4 gene CTD PMID:28505145 bortezomib increases expression ISO RGD:1313282 6480464 Bortezomib results in increased expression of MAP4K4 mRNA CTD PMID:20977926 bucladesine multiple interactions ISO RGD:1313282 6480464 [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of MAP4K4 mRNA CTD PMID:20823114 caffeine decreases phosphorylation ISO RGD:1313282 6480464 Caffeine results in decreased phosphorylation of MAP4K4 protein CTD PMID:35688186 cannabidiol multiple interactions ISO RGD:1313282 6480464 [Cannabidiol co-treated with moringin] results in decreased expression of MAP4K4 mRNA CTD PMID:30096889 captan decreases expression ISO RGD:1313283 6480464 Captan results in decreased expression of MAP4K4 mRNA CTD PMID:31558096 carbamazepine affects expression ISO RGD:1313282 6480464 Carbamazepine affects the expression of MAP4K4 mRNA CTD PMID:24752500 carbon nanotube increases expression ISO RGD:1313283 6480464 Nanotubes, Carbon analog results in increased expression of MAP4K4 mRNA CTD PMID:25554681 cerium trichloride increases expression ISO RGD:1313283 6480464 cerous chloride results in increased expression of MAP4K4 mRNA, cerous chloride results in increased expression of MAP4K4 protein CTD PMID:21656643 chloroprene decreases expression EXP 6480464 Chloroprene results in decreased expression of MAP4K4 mRNA CTD PMID:23125180 choline multiple interactions ISO RGD:1313283 6480464 [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of MAP4K4 mRNA CTD PMID:20938992 chrysene multiple interactions ISO RGD:1313283 6480464 [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MAP4K4 mRNA CTD PMID:27858113 cisplatin decreases expression ISO RGD:1313282 6480464 Cisplatin results in decreased expression of MAP4K4 mRNA CTD PMID:19561079 copper atom multiple interactions ISO RGD:1313282 6480464 [Chelating Agents binds to Copper] which results in increased expression of MAP4K4 mRNA CTD PMID:30911355 copper(0) multiple interactions ISO RGD:1313282 6480464 [Chelating Agents binds to Copper] which results in increased expression of MAP4K4 mRNA CTD PMID:30911355 copper(II) sulfate decreases expression ISO RGD:1313282 6480464 Copper Sulfate results in decreased expression of MAP4K4 mRNA CTD PMID:19549813 coumarin decreases phosphorylation ISO RGD:1313282 6480464 coumarin results in decreased phosphorylation of MAP4K4 protein CTD PMID:35688186 coumestrol multiple interactions ISO RGD:1313282 6480464 [Coumestrol co-treated with 2, 3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of MAP4K4 mRNA CTD PMID:19167446 coumestrol decreases expression ISO RGD:1313282 6480464 Coumestrol results in decreased expression of MAP4K4 mRNA CTD PMID:19167446 cyclosporin A decreases expression ISO RGD:1313282 6480464 Cyclosporine results in decreased expression of MAP4K4 mRNA CTD PMID:25562108 , PMID:27989131 dibenz[a,h]anthracene increases expression ISO RGD:1313283 6480464 1 more ... CTD PMID:26377693 dibenzo[a,l]pyrene decreases expression ISO RGD:1313283 6480464 dibenzo(a, l)pyrene results in decreased expression of MAP4K4 mRNA CTD PMID:25908611 diclofenac affects expression ISO RGD:1313282 6480464 Diclofenac affects the expression of MAP4K4 mRNA CTD PMID:24752500 dorsomorphin multiple interactions ISO RGD:1313282 6480464 [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAP4K4 mRNA CTD PMID:27188386 doxorubicin increases expression ISO RGD:1313282 6480464 Doxorubicin results in increased expression of MAP4K4 mRNA CTD PMID:29803840 Enterolactone multiple interactions ISO RGD:1313282 6480464 [Coumestrol co-treated with 2, 3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of MAP4K4 mRNA CTD PMID:19167446 epoxiconazole increases expression ISO RGD:1313283 6480464 epoxiconazole results in increased expression of MAP4K4 mRNA CTD PMID:35436446 ethanol affects splicing ISO RGD:1313283 6480464 Ethanol affects the splicing of MAP4K4 mRNA CTD PMID:30319688 ethanol multiple interactions ISO RGD:1313283 6480464 [Carbon Tetrachloride co-treated with Ethanol] results in increased expression of MAP4K4 mRNA, Ethanol affects the expression of and affects the splicing of MAP4K4 mRNA CTD PMID:30319688 , PMID:30517762 ethanol increases expression ISO RGD:1313283 6480464 Ethanol results in increased expression of MAP4K4 mRNA CTD PMID:30319688 ethyl methanesulfonate increases expression ISO RGD:1313282 6480464 Ethyl Methanesulfonate results in increased expression of MAP4K4 mRNA CTD PMID:23649840 fenthion decreases expression ISO RGD:1313283 6480464 Fenthion results in decreased expression of MAP4K4 mRNA CTD PMID:34813904 fenvalerate increases expression EXP 6480464 fenvalerate results in increased expression of MAP4K4 mRNA CTD PMID:30307764 folic acid multiple interactions ISO RGD:1313283 6480464 [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of MAP4K4 mRNA CTD PMID:20938992 formaldehyde decreases expression ISO RGD:1313282 6480464 Formaldehyde results in decreased expression of MAP4K4 mRNA CTD PMID:20655997 formaldehyde increases expression ISO RGD:1313282 6480464 Formaldehyde results in increased expression of MAP4K4 mRNA CTD PMID:23649840 fulvestrant multiple interactions ISO RGD:1313282 6480464 [bisphenol A co-treated with Fulvestrant] affects the methylation of MAP4K4 gene CTD PMID:31601247 furan increases methylation EXP 6480464 furan results in increased methylation of MAP4K4 gene CTD PMID:22079235 gallic acid decreases expression ISO RGD:1313282 6480464 Gallic Acid results in decreased expression of MAP4K4 mRNA CTD PMID:34408198 gamma-hexachlorocyclohexane decreases expression EXP 6480464 Hexachlorocyclohexane results in decreased expression of MAP4K4 mRNA CTD PMID:17785943 hexadecanoic acid multiple interactions ISO RGD:1313282 6480464 [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of MAP4K4 mRNA CTD PMID:30547786 indole-3-methanol affects expression EXP 6480464 indole-3-carbinol affects the expression of MAP4K4 mRNA CTD PMID:21396975 indometacin decreases expression ISO RGD:1313282 6480464 Indomethacin results in decreased expression of MAP4K4 mRNA CTD PMID:16984733 L-methionine multiple interactions ISO RGD:1313283 6480464 [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of MAP4K4 mRNA CTD PMID:20938992 lead diacetate increases expression ISO RGD:1313283 6480464 lead acetate results in increased expression of MAP4K4 mRNA CTD PMID:21829687 lead(0) affects splicing ISO RGD:1313282 6480464 Lead affects the splicing of MAP4K4 mRNA CTD PMID:28903495 lead(2+) affects splicing ISO RGD:1313282 6480464 Lead affects the splicing of MAP4K4 mRNA CTD PMID:28903495 medroxyprogesterone acetate multiple interactions ISO RGD:1313282 6480464 [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of MAP4K4 mRNA CTD PMID:20823114 menadione affects expression ISO RGD:1313282 6480464 Vitamin K 3 affects the expression of MAP4K4 mRNA CTD PMID:20044591 mercury dibromide increases expression ISO RGD:1313282 6480464 mercuric bromide results in increased expression of MAP4K4 mRNA CTD PMID:26272509 methotrexate increases expression ISO RGD:1313282 6480464 Methotrexate results in increased expression of MAP4K4 mRNA CTD PMID:21678067 methyl methanesulfonate increases expression ISO RGD:1313282 6480464 Methyl Methanesulfonate results in increased expression of MAP4K4 mRNA CTD PMID:23649840 methylmercury chloride increases expression ISO RGD:1313282 6480464 methylmercuric chloride results in increased expression of MAP4K4 mRNA CTD PMID:23179753 , PMID:28001369 N-methyl-4-phenylpyridinium decreases expression ISO RGD:1313282 6480464 1-Methyl-4-phenylpyridinium results in decreased expression of MAP4K4 mRNA CTD PMID:24810058 N-nitrosodiethylamine increases expression ISO RGD:1313283 6480464 Diethylnitrosamine results in increased expression of MAP4K4 mRNA CTD PMID:24535843 nickel atom increases expression ISO RGD:1313282 6480464 Nickel results in increased expression of MAP4K4 mRNA CTD PMID:25583101 nitrates increases expression EXP 6480464 Nitrates results in increased expression of MAP4K4 mRNA CTD PMID:30022042 ochratoxin A decreases expression ISO RGD:1313282 6480464 ochratoxin A results in decreased expression of MAP4K4 mRNA CTD PMID:30559759 oleic acid multiple interactions ISO RGD:1313282 6480464 [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of MAP4K4 mRNA CTD PMID:30547786 orphenadrine affects expression EXP 6480464 Orphenadrine affects the expression of MAP4K4 mRNA CTD PMID:23665939 oxaliplatin increases expression EXP 6480464 oxaliplatin results in increased expression of MAP4K4 mRNA CTD PMID:25729387 oxaliplatin multiple interactions EXP 6480464 [oxaliplatin co-treated with Topotecan] results in increased expression of MAP4K4 mRNA CTD PMID:25729387 ozone multiple interactions ISO RGD:1313282 6480464 [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone] results in increased expression of MAP4K4 mRNA more ... CTD PMID:32699268 paracetamol affects expression ISO RGD:1313283 6480464 Acetaminophen affects the expression of MAP4K4 mRNA CTD PMID:17562736 pirinixic acid multiple interactions ISO RGD:1313283 6480464 PPARA protein affects the reaction [pirinixic acid results in increased expression of MAP4K4 mRNA] CTD PMID:21318169 pirinixic acid increases expression ISO RGD:1313283 6480464 pirinixic acid results in increased expression of MAP4K4 mRNA CTD PMID:18301758 more ... potassium dichromate decreases expression ISO RGD:1313283 6480464 Potassium Dichromate results in decreased expression of MAP4K4 mRNA CTD PMID:23608068 progesterone multiple interactions ISO RGD:1313282 6480464 [Estradiol co-treated with Progesterone] results in decreased expression of MAP4K4 mRNA CTD PMID:20660070 quercetin decreases expression ISO RGD:1313282 6480464 Quercetin results in decreased expression of MAP4K4 mRNA CTD PMID:21632981 resveratrol multiple interactions ISO RGD:1313282 6480464 [Plant Extracts co-treated with Resveratrol] results in increased expression of MAP4K4 mRNA CTD PMID:23557933 SB 431542 multiple interactions ISO RGD:1313282 6480464 [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAP4K4 mRNA CTD PMID:27188386 sertraline multiple interactions ISO RGD:1313282 6480464 MAP4K4 mutant form inhibits the reaction [Sertraline results in increased cleavage of CASP4 protein] more ... CTD PMID:24865413 sertraline decreases expression ISO RGD:1313282 6480464 Sertraline results in decreased expression of MAP4K4 mRNA CTD PMID:24865413 silicon dioxide increases expression ISO RGD:1313283 6480464 Silicon Dioxide results in increased expression of MAP4K4 mRNA CTD PMID:23221170 sodium arsenate increases expression ISO RGD:1313283 6480464 sodium arsenate results in increased expression of MAP4K4 mRNA CTD PMID:30953684 sodium arsenite increases expression ISO RGD:1313282 6480464 sodium arsenite results in increased expression of MAP4K4 mRNA CTD PMID:24431212 sodium arsenite decreases expression ISO RGD:1313283 6480464 sodium arsenite results in decreased expression of MAP4K4 mRNA CTD PMID:18812580 Soman increases expression EXP 6480464 Soman results in increased expression of MAP4K4 mRNA CTD PMID:19281266 sulfates multiple interactions ISO RGD:1313282 6480464 [Soot co-treated with Sulfates] affects the methylation of MAP4K4 promoter CTD PMID:25395096 sulfates affects methylation ISO RGD:1313282 6480464 Sulfates affects the methylation of MAP4K4 promoter CTD PMID:25395096 tetrachloromethane multiple interactions EXP 6480464 schizandrin B inhibits the reaction [Carbon Tetrachloride results in increased expression of MAP4K4 mRNA] CTD PMID:31150632 tetrachloromethane increases expression ISO RGD:1313283 6480464 Carbon Tetrachloride results in increased expression of MAP4K4 mRNA CTD PMID:31919559 tetrachloromethane increases expression EXP 6480464 Carbon Tetrachloride results in increased expression of MAP4K4 mRNA CTD PMID:31150632 tetrachloromethane multiple interactions ISO RGD:1313283 6480464 [Carbon Tetrachloride co-treated with Ethanol] results in increased expression of MAP4K4 mRNA CTD PMID:30517762 tetraphene multiple interactions ISO RGD:1313283 6480464 [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MAP4K4 mRNA CTD PMID:27858113 thioacetamide increases expression EXP 6480464 Thioacetamide results in increased expression of MAP4K4 mRNA CTD PMID:23411599 , PMID:34492290 topotecan multiple interactions EXP 6480464 [oxaliplatin co-treated with Topotecan] results in increased expression of MAP4K4 mRNA CTD PMID:25729387 topotecan increases expression EXP 6480464 Topotecan results in increased expression of MAP4K4 mRNA CTD PMID:25729387 tributylstannane decreases expression ISO RGD:1313282 6480464 tributyltin results in decreased expression of MAP4K4 mRNA CTD PMID:27678064 trichostatin A increases expression ISO RGD:1313282 6480464 trichostatin A results in increased expression of MAP4K4 mRNA CTD PMID:24935251 , PMID:26272509 trichostatin A multiple interactions ISO RGD:1313282 6480464 [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAP4K4 mRNA CTD PMID:27188386 troglitazone increases expression ISO RGD:1313283 6480464 troglitazone results in increased expression of MAP4K4 mRNA CTD PMID:17569031 tungsten decreases expression ISO RGD:1313283 6480464 Tungsten results in decreased expression of MAP4K4 mRNA CTD PMID:30912803 valproic acid decreases methylation ISO RGD:1313282 6480464 Valproic Acid results in decreased methylation of MAP4K4 gene CTD PMID:29154799 valproic acid affects splicing EXP 6480464 Valproic Acid affects the splicing of MAP4K4 mRNA CTD PMID:29427782 valproic acid decreases expression ISO RGD:1313282 6480464 Valproic Acid results in decreased expression of MAP4K4 mRNA CTD PMID:23179753 more ... valproic acid increases expression ISO RGD:1313282 6480464 Valproic Acid results in increased expression of MAP4K4 mRNA CTD PMID:26272509 valproic acid affects expression ISO RGD:1313282 6480464 Valproic Acid affects the expression of MAP4K4 mRNA CTD PMID:25979313 vanadium atom decreases expression ISO RGD:1313282 6480464 Vanadium results in decreased expression of MAP4K4 mRNA CTD PMID:19000753 vanadium(0) decreases expression ISO RGD:1313282 6480464 Vanadium results in decreased expression of MAP4K4 mRNA CTD PMID:19000753 vinclozolin affects expression EXP 6480464 vinclozolin affects the expression of MAP4K4 mRNA CTD PMID:19015723 vinclozolin increases expression EXP 6480464 vinclozolin results in increased expression of MAP4K4 mRNA CTD PMID:20566332 vinclozolin decreases expression EXP 6480464 vinclozolin results in decreased expression of MAP4K4 mRNA CTD PMID:23034163 vincristine increases expression ISO RGD:1313282 6480464 Vincristine results in increased expression of MAP4K4 mRNA CTD PMID:23649840 vorinostat decreases expression ISO RGD:1313282 6480464 vorinostat results in decreased expression of MAP4K4 mRNA CTD PMID:27188386
